Page 117 - Memoria FEHH - SEHH 2017

GRUPO ESPAÑOL DE LINFOMAS Y TRASPLANTE AUTÓLOGO DE MÉDULA ÓSEA (GELTAMO)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
González de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernández A, Freue JM, Garrote H, López L, Martín-Moreno AM, Rodríguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO- IPI. Br J Haematol. 2017 Mar;176(6):918-28. PMID: 28106247.
• Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO). Guidelines for diagnosis, prevention and management of central nervous system involve- ment in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017 Feb;102(2):235-45. PMID: 27846613.
• Cabrero M, Martín A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Pérez-López E, López-Godino O, Conde E, Caballero D. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced- Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-9. PMID: 27771496.
• Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, González-Medina J, Revilla N, Sampol A, Domingo- Domenech E, de la Cruz F, Morales A, Rodríguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Co- morbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/ refractory Hodgkin’s lymphoma in patients older than 50 years. Ann Hematol. 2017 Jan;96(1):9-16. PMID: 27752822.
• González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea). Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. Acta Haematol. 2016;136(2):76-84. PMID: 27188649.
• Martínez C, Díaz-López A, Rodríguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapie- dra A, Domingo-Domenech E, Rodríguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation (GELTAMO). Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6):859-67. PMID: 27185197.
• González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. Ann Hematol. 2016 May;95(6):893-9. PMID: 27025508.
• Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa- associated lymphoid tissue lymphoma. Blood. 2017 Oct 12;130(15):1772-4.
• Salar A, Arcaini L, López-Guillermo A. Consolidated and innovative approaches in lymphoma. Indolent non- follicular lymphomas. Drugs Cell Therapies Hematology. 2016;4(1): 59-67.
• Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López
117